CS
FATE icon

Candriam SCA’s Fate Therapeutics FATE Stock Holding History

Candriam SCA’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-460,436
Closed -$4.65M – 896
2022
Q4 		$4.65M Hold
460,436
– – 0.03% 394
2022
Q3 		$10.3M Buy
460,436
+236,403
+106% +$6.83M 0.07% 262
2022
Q2 		$5.55M Sell
224,033
-19,407
-8% -$535K 0.05% 313
2022
Q1 		$9.44M Sell
243,440
-7,297
-3% -$283K 0.06% 267
2021
Q4 		$14.7M Hold
250,737
– – 0.09% 214
2021
Q3 		$14.9M Hold
250,737
– – 0.1% 217
2021
Q2 		$21.8M Sell
250,737
-19,370
-7% -$1.56M 0.15% 163
2021
Q1 		$23.6M Sell
270,107
-4
-0% -$383 0.2% 132
2020
Q4 		$24.6M Buy
+270,111
New +$16.8M 0.19% 133

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Candriam SCA's FATE Position: Q1 2023 in Review

Candriam SCA sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 460,436 shares — an estimated $4.65M sold.

Candriam SCA first reported a position in FATE in Q4 2020 and held it in 9 quarters. The position peaked at $24.6M in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Candriam SCA reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Candriam SCA sold 460,436 Fate Therapeutics shares in Q1 2023, an estimated $4.65M.
  • Candriam SCA first reported a position in Fate Therapeutics in Q4 2020 and held it in 9 quarters.
  • Candriam SCA's Fate Therapeutics position peaked at $24.6M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.